



## The Role of Metabolites in Translational and Clinical Pharmacology

Guest Editors:

**Dr. Mayur K. Ladumor**

**Dr. Xinning Yang**

**Dr. Eva Berglund**

**Prof. Dr. Rheem A. Totah**

### Message from the Guest Editors

This Special Issue aims to provide a comprehensive overview of the importance of drug metabolites in drug discovery and development within translational and clinical pharmacology domains. We invite original research articles, reviews, and short communications related to the field of metabolites.

Topics of interest include, but are not limited to, the following areas:

Deadline for manuscript  
submissions:

**15 July 2024**

- Absorption, distribution, metabolism, and excretion (ADME) or PK studies of drug metabolites.
- In vitro or in vivo evaluation of drug metabolites as substrates or perpetrators (inhibitors or inducers) of DMET proteins.
- Prediction of PK of drug metabolites in healthy or special populations using physiologically based pharmacokinetic (PBPK) models.
- Prediction of the DDI potential of drug metabolites using basic, static mechanistic, or dynamic PBPK models.
- Endogenous biomarkers for assessing the DMET-mediated DDI potential.
- Use of metabolite monitoring in DDI studies to improve the mechanistic interpretation of results.
- Mechanistic PK and PK/PD modeling of drug metabolites or parent metabolites.





an Open Access Journal by MDPI

## Editor-in-Chief

### Dr. Amedeo Lonardo

1. Formerly Director of the Simple Operating Unit "Metabolic Syndrome", Azienda Ospedaliero-Universitaria, 41126 Modena, Italy  
2. Formerly Professor of Internal Medicine, School of Specialization of Allergology and Clinical Immunology, University of Modena and Reggio Emilia, 41121 Modena, Italy

## Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Biochemistry & Molecular Biology*) / CiteScore - Q2 (*Endocrinology, Diabetes and Metabolism*)

## Contact Us

Metabolites Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/metabolites](http://mdpi.com/journal/metabolites)  
[metabolites@mdpi.com](mailto:metabolites@mdpi.com)  
X@MetabolitesMDPI